Delivery Order SPE2DB24D2205-SPE2DB25FEFJU
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,030.79 for Enbrel 25 mg/0.5 mL syringes on July 29, 2025, with completion targeted for July 30, 2025. This firm fixed-price contract, with no set-aside designation, represents a competitive award for pharmaceutical supply to support federal medical procurement needs. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $58,286.34 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Enbrel 50 mg/mL syringes. The contract employs firm fixed pricing with no set-aside designation and is scheduled for completion by August 5, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $9,158.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Enbrel 50 mg/ml syringes. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 21, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a near-term pharmaceutical supply requirement within the military healthcare supply chain. This award is issued under...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency's Medical Supply Chain on July 29, 2025, for the supply of Enbrel Surclk 50mg in quantities of four units. This firm fixed-price delivery order, valued at $15,655.75, represents a non-set-aside competitive award with an ultimate completion date of July 30, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $5,504.80 firm fixed price delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml syringes, with an ultimate completion date of August 19, 2025. This non-set-aside contract represents a direct award to the pharmaceutical distributor, which maintains its corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Enbrel Surclk 50mg in a quantity of four units, with a ceiling value of $62,380.74. This firm fixed-price delivery order, which is not set-aside, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and is scheduled for completion by September 10, 2025. The contract represents a routine pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $19,526.18 to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL syringes, with an ultimate completion date of July 25, 2025. This non-set-aside, competitively awarded contract reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical procurement. The award represents a firm fixed-price delivery order, consistent with the company's established pattern of fulfilling pharmaceutical supply...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $34,598.52 to AmerisourceBergen Drug Corp for the supply of Enbrel Surclk 50mg in quantities of four units. This firm fixed-price delivery order, issued on August 4, 2025, with an ultimate completion date of August 29, 2025, was competitively awarded with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $29,419.28 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Enbrel 50 mg/ml syringes. The contract, which carries an ultimate completion date of August 8, 2025, represents a non-set-aside, competitively awarded procurement with performance fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a $23,699.92 delivery order to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL syringes, with an ultimate completion date of August 19, 2025. This is a firm fixed price, non-set-aside contract awarded competitively on August 18, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEFJUDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $5,486 delivery order on July 24, 2025, for Enbrel 25 mg/0.5 mL syringes under a firm fixed price contract type with no set-aside designation. The order, designated as a child contract action, is set for completion by July 25, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle valued through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to fulfill complex medical supply requirements through open, competitive procurement processes. This award reflects the company's ongoing role as a primary supplier of specialty medications and medical commodities to the Defense Health Agency and other government healthcare systems through the DLA's flexible contracting vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 7/24/25 |